We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?
Read MoreHide Full Article
Key Takeaways
ISRG's Q3 earnings are expected to rise 8.75% to $2.61 per share, with sales projected to grow 15% to $2.88B.
ISRG's Q3 performance may benefit from international procedure growth and strong da Vinci 5 demand.
ISRG's Q3 margins may face pressure from China pricing challenges, higher freight costs and increased R&D.
Intuitive Surgical (ISRG - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 20, after the market closes. The company’s performance is expected to reflect continued adoption of robotic-assisted surgery, including its da Vinci and Ion platforms. However, moderating U.S. procedure growth, competitive pressures in China and a premium valuation could influence investor sentiment.
Intuitive Surgical’s third-quarter results are likely to reflect the balance between continued procedure growth, system demand and recurring revenue strength, and headwinds from moderating U.S. activity, China-related pricing pressure and higher costs. Management’s commentary on regional procedure trends, system placements and gross margins should provide important clues about the sustainability of quarterly growth and the company’s ability to meet consensus estimates.
Stock Performance and Earnings Surprise History
Intuitive Surgical’s shares gained 2.3% during the third quarter compared with the Zacks Medical Instruments industry’s 13.8% growth. The stock outperformed Stryker (SYK - Free Report) , which declined 12.5%, but narrowly exceeded GE HealthCare Technologies Inc. (GEHC - Free Report) , which gained 2.1%.
Image Source: Zacks Investment Research
ISRG has a strong earnings surprise record. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.53%. This track record provides a constructive backdrop, although past beats do not guarantee another earnings surprise.
Image Source: Zacks Investment Research
Consensus Estimates and Revisions
The Zacks Consensus Estimate for third-quarter 2026 earnings is pegged at $2.61 per share, indicating growth of 8.75% from the year-ago quarter, according to the supplied estimates. The consensus estimate for revenues is pinned at $2.88 billion, implying growth of 15%.
The EPS estimate has remained unchanged at $2.61 over the past seven days. This stability indicates that the near-term earnings outlook has remained largely unchanged during the period, although the direction of future estimate revisions remains uncertain.
Image Source: Zacks Investment Research
Key Factors Shaping ISRG’s Q3 Results
Procedure Growth and Utilization: Intuitive Surgical’s third-quarter performance is likely to have been influenced by the pace of procedure growth, particularly in the United States, where demand moderated in the second quarter. U.S. da Vinci procedure growth slowed to 12%, as patients appeared to defer certain procedures amid changes in coverage and premium dynamics.
This trend may have continued into the third quarter, potentially limiting recurring revenue growth from instruments and accessories. In contrast, international da Vinci procedures grew 20% in the second quarter, with Europe and Asia each reporting 20% growth. Sustained international momentum is likely to have partly offset softer U.S. demand, although the extent of this contribution remains uncertain.
System Placements and Revenue Mix: Strong demand for newer platforms supported Intuitive Surgical’s second-quarter placements of 468 da Vinci systems and 55 Ion systems. This momentum is likely to have supported system revenues in the third quarter, although customer purchasing decisions and capital budget constraints may have influenced placement volumes.
Adoption of da Vinci 5 could have contributed to system sales, while demand for the lower-cost XiR platform may have supported placements among budget-conscious customers. The number of reported placements and the mix of systems sold may indicate whether capital equipment demand remained strong enough to support recurring revenue growth.
Ion Procedures and International Demand: Ion procedures increased 36% in the second quarter, making utilization growth an important contributor to the company’s quarterly performance. Continued adoption of the platform is likely to have supported recurring revenues in the third quarter, although the magnitude of this contribution will become clearer when results are reported. International markets might have also provided support, given the strong procedure growth in the second quarter. Investors should assess whether these growth drivers were sufficient to offset moderation in the U.S. market.
Pricing Pressure and Margins: China’s challenging operating environment is likely to have remained a headwind in the third quarter, with lower tender activity, stronger domestic competition and policy-driven pricing pressure potentially affecting system placements and revenue mix. Cost pressures also remain important. Management cited higher freight and semiconductor memory costs, alongside product and regional mix, as factors affecting profitability in the second quarter.
Although the company raised its 2026 adjusted gross margin outlook to 68-69%, third-quarter results are likely to indicate whether revenue growth and operating execution were sufficient to absorb these pressures. Higher research and development spending may have affected operating leverage and earnings growth.
What Our Model Unveils for ISRG Stock
Our proven model does not conclusively predict an earnings beat for Intuitive Surgical this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Intuitive Surgical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
ISRG is trading at a forward 12-month price-to-earnings (P/E F12M) of 35.87X compared with 27.19X for its industry. The valuation premium reflects investor expectations for sustained growth but leaves less room for disappointment.
Image Source: Zacks Investment Research
Stryker is trading at 17.30X P/E F12M and GE HealthCare at 12.89X. These lower multiples do not necessarily indicate that ISRG is overvalued relative to its peers, given differences in business mix.
Conclusion
Intuitive Surgical’s expanding procedure base, strong earnings-surprise history and continued platform adoption support its long-term investment case. Nevertheless, moderating U.S. demand, intensifying competition in China, rising investment needs and a premium valuation warrant caution ahead of the results. Existing shareholders may consider holding their positions, while prospective investors should evaluate procedure growth, margin performance and management’s updated outlook before initiating a position.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 20, after the market closes. The company’s performance is expected to reflect continued adoption of robotic-assisted surgery, including its da Vinci and Ion platforms. However, moderating U.S. procedure growth, competitive pressures in China and a premium valuation could influence investor sentiment.
Intuitive Surgical’s third-quarter results are likely to reflect the balance between continued procedure growth, system demand and recurring revenue strength, and headwinds from moderating U.S. activity, China-related pricing pressure and higher costs. Management’s commentary on regional procedure trends, system placements and gross margins should provide important clues about the sustainability of quarterly growth and the company’s ability to meet consensus estimates.
Stock Performance and Earnings Surprise History
Intuitive Surgical’s shares gained 2.3% during the third quarter compared with the Zacks Medical Instruments industry’s 13.8% growth. The stock outperformed Stryker (SYK - Free Report) , which declined 12.5%, but narrowly exceeded GE HealthCare Technologies Inc. (GEHC - Free Report) , which gained 2.1%.
Image Source: Zacks Investment Research
ISRG has a strong earnings surprise record. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.53%. This track record provides a constructive backdrop, although past beats do not guarantee another earnings surprise.
Image Source: Zacks Investment Research
Consensus Estimates and Revisions
The Zacks Consensus Estimate for third-quarter 2026 earnings is pegged at $2.61 per share, indicating growth of 8.75% from the year-ago quarter, according to the supplied estimates. The consensus estimate for revenues is pinned at $2.88 billion, implying growth of 15%.
The EPS estimate has remained unchanged at $2.61 over the past seven days. This stability indicates that the near-term earnings outlook has remained largely unchanged during the period, although the direction of future estimate revisions remains uncertain.
Image Source: Zacks Investment Research
Key Factors Shaping ISRG’s Q3 Results
Procedure Growth and Utilization: Intuitive Surgical’s third-quarter performance is likely to have been influenced by the pace of procedure growth, particularly in the United States, where demand moderated in the second quarter. U.S. da Vinci procedure growth slowed to 12%, as patients appeared to defer certain procedures amid changes in coverage and premium dynamics.
This trend may have continued into the third quarter, potentially limiting recurring revenue growth from instruments and accessories. In contrast, international da Vinci procedures grew 20% in the second quarter, with Europe and Asia each reporting 20% growth. Sustained international momentum is likely to have partly offset softer U.S. demand, although the extent of this contribution remains uncertain.
System Placements and Revenue Mix: Strong demand for newer platforms supported Intuitive Surgical’s second-quarter placements of 468 da Vinci systems and 55 Ion systems. This momentum is likely to have supported system revenues in the third quarter, although customer purchasing decisions and capital budget constraints may have influenced placement volumes.
Adoption of da Vinci 5 could have contributed to system sales, while demand for the lower-cost XiR platform may have supported placements among budget-conscious customers. The number of reported placements and the mix of systems sold may indicate whether capital equipment demand remained strong enough to support recurring revenue growth.
Ion Procedures and International Demand: Ion procedures increased 36% in the second quarter, making utilization growth an important contributor to the company’s quarterly performance. Continued adoption of the platform is likely to have supported recurring revenues in the third quarter, although the magnitude of this contribution will become clearer when results are reported. International markets might have also provided support, given the strong procedure growth in the second quarter. Investors should assess whether these growth drivers were sufficient to offset moderation in the U.S. market.
Pricing Pressure and Margins: China’s challenging operating environment is likely to have remained a headwind in the third quarter, with lower tender activity, stronger domestic competition and policy-driven pricing pressure potentially affecting system placements and revenue mix. Cost pressures also remain important. Management cited higher freight and semiconductor memory costs, alongside product and regional mix, as factors affecting profitability in the second quarter.
Although the company raised its 2026 adjusted gross margin outlook to 68-69%, third-quarter results are likely to indicate whether revenue growth and operating execution were sufficient to absorb these pressures. Higher research and development spending may have affected operating leverage and earnings growth.
What Our Model Unveils for ISRG Stock
Our proven model does not conclusively predict an earnings beat for Intuitive Surgical this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Intuitive Surgical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: ISRG carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Valuation and Investment Outlook
ISRG is trading at a forward 12-month price-to-earnings (P/E F12M) of 35.87X compared with 27.19X for its industry. The valuation premium reflects investor expectations for sustained growth but leaves less room for disappointment.
Image Source: Zacks Investment Research
Stryker is trading at 17.30X P/E F12M and GE HealthCare at 12.89X. These lower multiples do not necessarily indicate that ISRG is overvalued relative to its peers, given differences in business mix.
Conclusion
Intuitive Surgical’s expanding procedure base, strong earnings-surprise history and continued platform adoption support its long-term investment case. Nevertheless, moderating U.S. demand, intensifying competition in China, rising investment needs and a premium valuation warrant caution ahead of the results. Existing shareholders may consider holding their positions, while prospective investors should evaluate procedure growth, margin performance and management’s updated outlook before initiating a position.